Regeneron Pharmaceuticals

Health Care Biotechnology Tarrytown, New York Last filing Feb 4, 2026 · FY2025

                    Revenue
                    FY2025
                
$14.3B
                    3y CAGR +5.6%
                    
                    P56
                    
                    n/a
                    
                    Net income
                    FY2025
                
$4.5B
                    Net margin +31.4%
                    
                    P97
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$40.6B
                    ROA +11.1%
                    
                    P75
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$5.0B
                    
                    n/a

18 yrs · FY2008–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

30 accounts · 1 year

Total assets $40.6B

Total liabilities $9.3B

Shareholders equity $31.3B

Account	2025	Trend
Assets
Cash and Cash Equivalents	21.7%
Accounts Receivable	40.0%
Inventory	22.3%
Prepaid Expenses	3.3%
Other Current Assets	12.7%
Total Current Assets	125.7%
Property,Plant and Equipment	35.7%
Intangible Assets	8.8%
Deferred Tax Assets	28.4%
Other Noncurrent Assets	12.7%
Total Assets	282.8%
Liabilities
Accounts Payable	6.5%
Accrued Liabilities	20.1%
Deferred Revenue	3.9%
Current Portion of Long Term Debt	13.8%
Other Current Liabilities	0.0%
Total Current Liabilities	30.5%
Long Term Debt	13.8%
Deferred Revenue Noncurrent	1.5%
Operating Lease Liabilities Noncurrent	5.0%
Other Noncurrent Liabilities	14.1%
Total Liabilities	64.9%
Equity
Preferred Stock	0.0%
Common Stock	0.0%
Additional Paid In Capital	97.6%
Retained Earnings	249.6%
Treasury Stock	129.8%
Accumulated Other Comprehensive Income	0.5%
Total Stockholders Equity	217.9%
Total Liabilitiesand Equity	282.8%

Income Statement

Revenue, expense, and profitability

19 accounts · 1 year

Revenue $14.3B

Operating income $3.6B

Net income $4.5B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	75.1%
Expenses Research and Development	40.8%
Expenses Selling,General and Administrative	18.8%
Expenses Depreciation and Amortization	3.8%
Expenses Share Based Compensation	6.9%
Expenses Operating Expenses	75.1%
Other Income Expense Operating Income	24.9%
Other Income Expense Interest Income	5.0%
Other Income Expense Interest Expense	0.3%
Other Income Expense Other Income/expense	11.8%
Other Income Expense Income Before Tax	36.5%
Income Tax Income Tax Expense	5.1%
net Income net Income	31.4%
net Income Comprehensive Income	32.0%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	0.7%
Earnings Per Share Weighted Average Shares Diluted	0.8%

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 1 year

Operating cash flow $5.0B

Investing cash flow $-629.1M

Financing cash flow $-3.7B

Account	2025	Trend
CashFlow
Operating Activities net Income	31.4%
Operating Activities Depreciation and Amortization	3.8%
Operating Activities Stock Based Compensation	6.9%
Operating Activities Deferred Income Taxes	-5.5%
Operating Activities Changes In Operating Assets and Liabilities	0.7%
Operating Activities net Cash From Operating Activities	34.7%
Investing Activities Business Acquisitions	0.0%
Investing Activities Purchases of Investments	76.4%
Investing Activities Proceeds From Sale of Investments	80.5%
Investing Activities net Cash From Investing Activities	-4.4%
Financing Activities Repurchase of Common Stock	24.0%
Financing Activities Dividends Paid	2.6%
Financing Activities Proceeds From Stock Issuance	4.4%
Financing Activities Tax Withholding On Stock Based Compensation	3.7%
Financing Activities Other Financing Activities	-0.1%
Financing Activities net Cash From Financing Activities	-25.9%
Cash Reconciliation Effect of Exchange Rate On Cash	0.0%
Cash Reconciliation net Change In Cash	4.4%
Cash Reconciliation Cash At Beginning of Period	21.8%
Cash Reconciliation Cash At End of Period	21.8%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+24.9%
Operating margin	+24.9%
Net margin	+31.4%
FCF margin	—
Growth
Revenue CAGR (3y)	+5.6%
Returns
ROE	+14.4%
ROA	+11.1%
ROIC	+9.6%
Liquidity
Current ratio	4.13x
Quick ratio	2.03x
Leverage
D/E	0.30x
Interest coverage	81.69x
Efficiency
Asset turnover	0.35x
Cash conversion cycle	+223d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Regeneron Pharmaceuticals

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history